Company intelligence / Profile preview

Emerge Health

Carlsbad, California, United Statesemergehealthco.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Emerge Diagnostics has developed EFA Technology that leverages electromyography with functional assessments to diagnose musculoskeletal disorders. Their programs have been used by major employers for over ten years, with enhanced telemedicine capabilities developed since 2017 and refined during the pandemic.

Therapeutic areas: OtherRheumatology
Industry: Physiological Monitoring

Drug pipeline

1 asset

TAVO-EP

Phase 2

Indications: Melanoma, Triple negative breast cancer, Squamous cell carcinoma head and neck cancer

Beyond the preview

Go deeper on Emerge Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emerge Health.

Explore the full profile